SC
MGX icon

Steven Cohen’s Metagenomi Therapeutics MGX Stock Holding History

Steven Cohen’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,726
Closed -$15.7K – 4673
2026
Q1 		$15.7K Sell
11,726
-14,863
-56% -$23.1K ﹤0.01% 3689
2025
Q4 		$43.1K Buy
+26,589
New +$57.6K ﹤0.01% 3795
2024
Q3 		– Sell
-99,002
Closed -$404K – 2401
2024
Q2 		$404K Sell
99,002
-272,098
-73% -$1.87M ﹤0.01% 1487
2024
Q1 		$3.92M Buy
+371,100
New +$4.27M 0.01% 1052

Other funds holding MGX

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Steven Cohen's MGX Position: Q2 2026 in Review

Steven Cohen sold out of Metagenomi Therapeutics (MGX) in Q2 2026, closing a stake of 11,726 shares — an estimated $15.7K sold.

Steven Cohen first reported a position in MGX in Q1 2024 and held it in 4 quarters. The position peaked at $3.92M in Q1 2024. 43 funds tracked by Wall St. Rank hold MGX as of Q2 2026.

  • Steven Cohen reported no remaining Metagenomi Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Steven Cohen sold 11,726 Metagenomi Therapeutics shares in Q2 2026, an estimated $15.7K.
  • Steven Cohen first reported a position in Metagenomi Therapeutics in Q1 2024 and held it in 4 quarters.
  • Steven Cohen's Metagenomi Therapeutics position peaked at $3.92M in Q1 2024.
  • 43 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.